HROW Stock Risk & Deep Value Analysis
Harrow Inc
Healthcare • Drug Manufacturers - Specialty & Generic
DVR Score
out of 10
What You Need to Know About HROW Stock
We analyzed Harrow Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran HROW through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
HROW Risk Analysis & Red Flags
What Could Go Wrong
The company's high debt levels, ongoing unprofitability, and significant cash burn could force further dilutive capital raises or make servicing debt unsustainable if Q1 2026 results and subsequent quarters fail to show a clear path to positive free cash flow, potentially leading to a significant stock price decline.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Ongoing unprofitability (negative P/E), despite revenue growth (based on Q4 2025 trends).
- ⚠
High debt-to-equity ratio (approx. 4.8x based on previous analysis), exacerbated by a recent $50M debt offering.
- ⚠
Analyst consensus Q1 2026 revenue estimate revised down 10.8% due to weaker volumes, indicating potential execution challenges.
- ⚠
Significant reliance on M&A for growth, requiring efficient integration and capital deployment.
Upcoming Risk Events
- 📅
Disappointing Q1 2026 earnings call, particularly on guidance given lower revenue estimates
- 📅
Increased debt burden or unfavorable terms for future financing needs
- 📅
Slower-than-expected integration of acquired assets, impacting profitability
When to Reconsider
- 🚪
Exit if Q1 2026 earnings report shows significant cash burn acceleration without a clear roadmap to profitability.
- 🚪
Sell if management provides significantly lowered full-year guidance (e.g., >15% below consensus) following Q1 results.
- 🚪
Exit if debt-to-equity ratio further increases significantly or if interest coverage ratios deteriorate sharply.
Unlock HROW Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Harrow Inc (HROW) Do?
Market Cap
$1.52B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
382
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
Visit Harrow Inc WebsiteInvestment Thesis
Harrow Inc. presents a compelling high-risk, high-reward opportunity to capitalize on the consolidation of the fragmented U.S. ophthalmic market. Its strategic M&A, specialized distribution, and focus on niche products position it for significant long-term growth and market leadership, despite current unprofitability and high debt. Success hinges on efficient integration, achieving economies of scale, and delivering positive free cash flow.
Is HROW Stock Undervalued?
Unlock the full AI analysis for HROW
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
HROW Price Targets & Strategy
12-Month Target
$55.00
Bull Case
$70.00
Bear Case
$30.00
Valuation Basis
Based on 3.5x projected FY2026 revenue of ~$450M (up from ~$300M in FY2025, factoring in acquisitions) using a conservative EV/Sales multiple for a growing but unprofitable pharma services company.
Entry Strategy
Consider dollar-cost averaging on dips towards the $38-$42 range, leveraging any near-term consolidation or weakness post-earnings. A more aggressive entry could be considered after Q1 2026 earnings if results beat lowered expectations.
Exit Strategy
Take partial profits at $60-$65, reassess above $70 based on improved profitability and debt reduction. Stop loss at $35 if financial performance deteriorates or competitive landscape shifts negatively.
Portfolio Allocation
5% for aggressive risk tolerance, 2% for moderate, 0% for conservative due to high financial risk profile.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is HROW Financially Healthy?
Profitability
Gross Margin
75.05%
Operating Margin
8.36%
Net Margin
-1.89%
Return on Equity
-10.00%
Revenue Growth
36.41%
EPS
$-0.16
Balance Sheet
Current Ratio
2.20
Quick Ratio
1.93
Debt/Equity
4.64
Total Debt
$5.20B
Cash & Equivalents
$5.20B
Cash Flow
Operating Cash Flow
$5.20B
Free Cash Flow
$5.20B
EBITDA
$5.20B
Other
Beta (Volatility)
0.34
Does HROW Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat is expanding as Harrow acquires more ophthalmic assets and integrates them into its specialized distribution network. The regulatory hurdles and established relationships for prescription drugs create switching costs for doctors and patients. However, patent expiry and competition from larger pharma companies pose long-term risks.
Moat Erosion Risks
- •Loss of patent protection or market exclusivity for key acquired drugs.
- •Competition from large pharmaceutical companies with greater R&D and marketing budgets.
- •Failure to successfully integrate acquired companies, leading to loss of value.
HROW Competitive Moat Analysis
Sign up to see competitive advantages
HROW Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral. While the previous analysis noted positive analyst sentiment, the current lack of fresh data and the Q1 revenue revision might introduce caution among retail investors.
Institutional Sentiment
Neutral. No recent upgrades/downgrades reported, but prior sentiment was positive. The downward revenue revision for Q1 may lead to a reassessment by institutions.
Insider Activity (Form 4)
No specific Form 4 filings reported in the last 90 days. This indicates a neutral stance from insiders for this period.
Options Flow
Normal options activity observed; no significant unusual put/call ratio or large block trades indicative of strong institutional positioning were reported.
Earnings Intelligence
Next Earnings
2026-05-11
Surprise Probability
Medium
Historical Earnings Pattern
Historically, the stock has reacted to M&A announcements and key product developments. Earnings reactions likely volatile given high-growth, unprofitable nature, with potential for significant moves on guidance or cash flow updates.
Key Metrics to Watch
Competitive Position
Top Competitor
BAUS (Bausch Health Companies Inc.) or other specialty pharma focused on ophthalmology.
Market Share Trend
Gaining market share through strategic acquisitions and product diversification within the ophthalmic market.
Valuation vs Peers
Difficult to compare directly on traditional profitability metrics (e.g., P/E) due to Harrow's unprofitability. Likely trading at a premium on EV/Sales compared to established, profitable peers, reflecting its growth potential, but at a discount to smaller, high-growth biotechs.
Competitive Advantages
- •Specialized focus on the fragmented ophthalmic market allowing for targeted M&A.
- •Proprietary distribution channels and relationships with ophthalmologists.
- •Portfolio of niche ophthalmic products with specific J-Codes for reimbursement.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive HROW Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Release on 2026-05-11
- •Conference Call on 2026-05-12 for Q1 2026 results
- •Potential new product launches or expanded distribution deals within 2026
Medium-Term (6-18 months)
- •Successful integration and synergy realization from recent acquisitions
- •Expansion of U.S. ophthalmic market share through organic growth and M&A
- •Achieving positive operating cash flow and reduced net losses
Long-Term (18+ months)
- •Consolidation of a significant portion of the fragmented U.S. ophthalmic market
- •Leveraging proprietary distribution network for competitive advantage
- •Establishment as a dominant player in specialized ophthalmology pharma
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for HROW?
- ✓
Acceleration in organic revenue growth (excluding acquisitions)
- ✓
Consistent improvement in gross and operating margins leading to net profitability
- ✓
Reduction in debt-to-EBITDA ratio and sustained positive free cash flow
Bull Case Analysis
See what could go right with Premium
Competing with HROW
See how Harrow Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Harrow Inc HROW | $1.5B | 6.1 | — | $5.2B | -1.9% | 36.4% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Harrow Inc Makes Money
Harrow Inc. operates as a specialized pharmaceutical company focused on the U.S. ophthalmic market. It acquires, develops, and commercializes prescription and non-prescription ophthalmic products. The company primarily makes money by selling these specialized eye care products to ophthalmologists, hospitals, and other healthcare providers, leveraging a direct sales force and efficient distribution network to serve a highly fragmented market. Its strategy involves consolidating smaller, niche products and companies within the eye care sector to achieve economies of scale and market dominance.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Harrow Inc (HROW)?
As of May 4, 2026, Harrow Inc has a DVR Score of 6.1 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Harrow Inc?
Harrow Inc's market capitalization is approximately $1.5B. The company operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.
What ticker symbol does Harrow Inc use?
HROW is the ticker symbol for Harrow Inc. The company trades on the NGM.
What is the risk level for HROW stock?
Our analysis rates Harrow Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is Harrow Inc's revenue growing?
Harrow Inc has reported revenue growth of 36.4%. The company is showing strong top-line momentum.
Is HROW stock profitable?
Harrow Inc has a profit margin of -1.9%. The company is currently unprofitable.
How often is the HROW DVR analysis updated?
Our AI-powered analysis of Harrow Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 4, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for HROW (Harrow Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.